Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Complete Research Overview Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors
And although GLP-1 drugs have an overall favorable benefit-risk profile when appropriately prescribed, they are not benign: Gastrointestinal effects are common, discontinuation is frequent in real-world settings, and regulators continue to monitor rarer concerns including gallbladder disease, pancreatitis, aspiration risk, and psychiatric symptoms
Both contain the same active ingredient and produce similar weight loss results
Theres also concern about cumulative liver effects with regular drinking, though GLP-1 agonists have some protective liver effects that may offset this
